Relay Medical Corp.
Relay Medical Announces Extension of Warrant Expiry Date
DGAP-News: Relay Medical Corp.
/ Key word(s): Miscellaneous
Toronto, Ontario–(Newsfile Corp. – October 25, 2019) – Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company“), a developer of MedTech innovation, announces that it intends to extend the expiry date of an aggregate of 7,570,500 previously issued warrants (the “Warrants“) at an exercise price of $0.30 for an additional twelve (12) months (the “Amendment“). The exercise price of the Warrants will remain unchanged. About Relay Medical Corp. Relay Medical is an evolving “Integrated Medtech Accelerator” headquartered in Toronto, Canada, advancing multiple opportunities for commercialization within a resource efficient infrastructure. Relay is also actively dedicated to scouting and reviewing strategic acquisitions complimentary to current infrastructure assets and intends to grow as a leading engine for MedTech innovation in the health technologies marketplace. Website: www.relaymedical.com Contact: Bernhard Langer Forward-looking Information Cautionary Statement Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for UXD described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49157 Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/49157News Source: Newsfile
25.10.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Relay Medical Corp. |
Canada | |
ISIN: | CA75943L1058 |
EQS News ID: | 897653 |
End of News | DGAP News Service |